TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05938465: Study of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an IPAA (PROF)

Sponsor: Exegi Pharma, LLC · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 50 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,072,360

Rescue Site Savings

+$705,500

Unlock Full NCT05938465 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05938465 Rescue Dossier →